Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Trial Profile

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dasiglucagon (Primary)
  • Indications Hypoglycaemia
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 23 Mar 2022 Primary endpoint has been met. (Nadir plasma glucose concentration within two hundred forty minutes after MMT for 80 ug and 200 ug), as per Results published in the Diabetes Care
  • 23 Mar 2022 Results published in the Diabetes Care
  • 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top